Drug intelligence / Profile preview

XH02

Development stage: Phase 1
Lead developer: Peking Union Medical College Hospital
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intravenous

Overview

XH02 is a novel messenger RNA (mRNA) drug under investigation for the treatment of hypoparathyroidism. Administered intravenously, the mRNA in XH02 is designed to be translated within the body into parathyroid hormone (PTH). This mechanism aims to provide replacement therapy for patients who have insufficient levels of endogenous PTH, thereby addressing the underlying cause of hypoparathyroidism.

Other names: parathyroid hormone 1-84 mRNAintravenous administration of PTH1-84 mRNA

Targets

PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)

Beyond the preview

Go deeper on XH02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XH02.

Explore the full profile